Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Dec 16, 2022
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-12-14−36,000→ 179,994 totalExercise: $2.87Exp: 2030-09-15→ Common Stock (36,000 underlying) - Exercise/Conversion
Common Stock
2022-12-14$2.87/sh+36,000$103,320→ 42,629 total
Footnotes (1)
- [F1]The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.